Ontak denileukin diftitox: Phase II data; marketed to treat persistent or recurrent CTCL

In a U.S. Phase II trial in 41 patients, 1 of 33 evaluable patients

Read the full 140 word article

How to gain access

Continue reading with a
two-week free trial.